{"id":"lansoprzole-amoxicillin-clarithromycin","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Diarrhea"},{"rate":"10-20","effect":"Nausea"},{"rate":"5-15","effect":"Abdominal pain"},{"rate":"5-10","effect":"Taste disturbance"},{"rate":"5-10","effect":"Headache"},{"rate":"1-3","effect":"Allergic reactions (amoxicillin)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion, creating an environment where antibiotics are more effective. Amoxicillin and clarithromycin are bactericidal and bacteriostatic antibiotics, respectively, that target H. pylori cell wall and protein synthesis. Together, this triple therapy achieves high eradication rates by combining acid suppression with dual antibiotic coverage.","oneSentence":"This triple-therapy combination eradicates Helicobacter pylori by suppressing gastric acid (lansoprazole) while simultaneously killing the bacteria with two antibiotics (amoxicillin and clarithromycin).","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:40.764Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori infection eradication in peptic ulcer disease"},{"name":"H. pylori-associated gastritis"}]},"trialDetails":[{"nctId":"NCT00990405","phase":"PHASE4","title":"Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia","status":"UNKNOWN","sponsor":"Korean College of Helicobacter and Upper Gastrointestinal Research","startDate":"2009-10","conditions":"Functional Dyspepsia, Helicobacter Pylori Infection","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Lansoprzole+Amoxicillin+Clarithromycin","genericName":"Lansoprzole+Amoxicillin+Clarithromycin","companyName":"Korean College of Helicobacter and Upper Gastrointestinal Research","companyId":"korean-college-of-helicobacter-and-upper-gastrointestinal-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple-therapy combination eradicates Helicobacter pylori by suppressing gastric acid (lansoprazole) while simultaneously killing the bacteria with two antibiotics (amoxicillin and clarithromycin). Used for Helicobacter pylori infection eradication in peptic ulcer disease, H. pylori-associated gastritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}